Importantly, the immunoliposomes used to target TRAMP-derived cancer cells were demonstrated to be nontoxic in vitro given that the viabilities of IL30-TRAMP-C1 cells treated with Empty-mPSCA NxPs or PBS (or untreated) were comparable (ANOVA: p > 0.05) (Supplementary Fig. 17). This evidence concerns the gene IL27 and cancer.